Health Care

Enliven Therapeutics’ CFO buys at $14.85 and sells near $38.50, showing disciplined liquidity management and confidence in the company’s oncology growth.

Insightful analysis of CFO Ignelzi Troy A.’s recent 5,500‑share buy in Rapport Therapeutics and its impact on the company’s Phase‑2 success, cash runway, and future outlook.

Pal’s insider buy signals cautious optimism amid steep stock decline; insider confidence, liquidity risks, and upcoming clinical milestones highlighted.

CRISPR Therapeutics CFO’s 25,000 RSU purchase signals long‑term confidence amid breakthrough Phase II data for CTX‑01 and early safety success for CTX‑02, hinting at future regulatory approvals and shareholder value growth.

Inside view of Kevin Bitterman’s 30k+ share sales at Disc Medicine amid a $80 rally, revealing insider liquidity tactics and investor implications.

ORIC CFO’s disciplined trade signals confidence: buying low at $4.36 and selling high at $13.53, underscoring a bullish outlook amid a 19.5% rally.

Insider option exercise by NIKI BIOSOLUTIONS director Philips Laura A signals strong merger confidence, boosting investor sentiment and potential valuation gains.

ADAR1 Capital’s steady $2.3 M buy‑in boosts Tenax Therapeutics to 8.5% ownership, signaling institutional confidence amid volatile shares and a promising pulmonary hypertension pipeline.

Executive insider buying by United Therapeutics CEO Martine Rothblatt shows strong long‑term confidence and underpins the company’s bullish biotech outlook.

Clene Inc. insider buying signals boost confidence in its ALS drug CNM‑Au8; CEO’s option exercise coincides with NDA filing and promising clinical data.